Grand Pharmaceutical Group (SEHK:512) - Aandelenkoers, Nieuws & Analyse

512 Overzicht aandelen

512 fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	1/6
Prestaties in het verleden	2/6
Financiële gezondheid	6/6
Dividenden	3/6

Beloningen

Trading at 57.8% below our estimate of its fair value

Earnings are forecast to grow 2.29% per year

Earnings have grown 12.9% per year over the past 5 years

Trading at good value compared to peers and industry

Risicoanalyse

Unstable dividend track record

Grand Pharmaceutical Group Limited Concurrenten

United Laboratories International Holdings

SEHK:3933

HK$19.5b

SSY Group

SEHK:2005

HK$11.2b

China Medical System Holdings

SEHK:867

HK$19.0b

Luye Pharma Group

SEHK:2186

HK$10.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Grand Pharmaceutical Group
Historische aandelenkoersen
Huidige aandelenkoers	HK$4.56
52 Week Hoogtepunt	HK$5.62
52 Week Laag	HK$3.17
Bèta	0.71
11 maand verandering	-12.31%
3 maanden verandering	4.83%
1 Jaar Verandering	1.33%
33 jaar verandering	-23.10%
5 jaar verandering	0.22%
Verandering sinds IPO	-82.46%

Recent nieuws en updates

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 19

Recent updates

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 19

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Jun 05

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

May 22

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Apr 25

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Mar 25

If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late

Jan 24

These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely

Dec 13

Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price

Nov 27

With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting

Oct 25

China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly

Sep 01

Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?

Jul 12

Rendement voor aandeelhouders

	512	HK Pharmaceuticals	HK Markt
7D	-1.7%	-7.2%	-1.0%
1Y	1.3%	-2.9%	15.0%

Rendement versus industrie: 512 exceeded the Hong Kong Pharmaceuticals industry which returned -2.9% over the past year.

Rendement versus markt: 512 underperformed the Hong Kong Market which returned 15% over the past year.

Prijsvolatiliteit

Is 512's price volatile compared to industry and market?
512 volatility
512 Average Weekly Movement	5.5%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.3%

Stabiele aandelenkoers: 512 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatiliteit in de loop van de tijd: 512's weekly volatility (6%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1995	10,775	Chao Zhou	www.grandpharm.com

Grand Pharmaceutical Group Limited, een investeringsholding, houdt zich bezig met onderzoek en ontwikkeling, productie en verkoop van farmaceutische preparaten en medische hulpmiddelen, biotechnologie en gezondheidsproducten, en farmaceutische grondstoffen. Het bedrijf biedt producten voor de luchtwegen, oogheelkunde, cerebro-cardiovasculaire spoedeisende hulp en biotechnologie. Het produceert en verkoopt farmaceutische producten, taurine, landbouwchemicaliën, chemische geneesmiddelen en aminozuurseries.

Grand Pharmaceutical Group Limited Samenvatting

Hoe verhouden de winst en inkomsten van Grand Pharmaceutical Group zich tot de beurswaarde?
512 fundamentele statistieken
Marktkapitalisatie	HK$16.11b
Inkomsten(TTM)	HK$2.41b
Inkomsten(TTM)	HK$10.59b

6.6x

Koers/Winstverhouding

1.5x

P/S-verhouding

Is 512 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
512 resultatenrekening (TTM)
Inkomsten	HK$10.59b
Kosten van inkomsten	HK$4.34b
Brutowinst	HK$6.25b
Overige uitgaven	HK$3.84b
Inkomsten	HK$2.41b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.69
Brutomarge	59.00%
Nettowinstmarge	22.75%
Schuld/Eigen Vermogen Verhouding	28.1%

Hoe presteerde 512 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

5.7%

Huidig dividendrendement

38%

Uitbetalingsratio

512 Overzicht aandelen

Beloningen

Risicoanalyse

Grand Pharmaceutical Group Limited Concurrenten

SEHK:3933

HK$19.5b

SEHK:2005

HK$11.2b

SEHK:867

HK$19.0b

SEHK:2186

HK$10.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA

National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11

Investor sentiment improves as stock rises 15%

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director

Recent updates

Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA

National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11

Investor sentiment improves as stock rises 15%

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough

Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director

First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023)

Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024

Grand Pharmaceutical Group Limited Announces Executive Changes

Executive Chairman recently bought HK$526k worth of stock

Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment

Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year

Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.26 per share

Executive Chairman recently bought HK$271k worth of stock

Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings

Executive Chairman recently bought HK$489k worth of stock

Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Executive Chairman recently bought HK$371k worth of stock

Executive Chairman recently bought HK$243k worth of stock

Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26

Dividend increased to HK$0.26

Executive Chairman recently bought HK$381k worth of stock

Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Full year 2023 earnings: EPS misses analyst expectations

Grand Pharmaceutical Group Limited Proposes Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024

Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024

Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA

Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002)

Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing

We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt

Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching

Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint

Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently

First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022)

Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate

Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023

Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China

Less than half of directors are independent

Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director

Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director

Less than half of directors are independent

Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14

Grand Pharmaceutical Group Limited Announces Board Changes

Upcoming dividend of HK$0.14 per share at 2.9% yield

Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray

Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?

Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021)

National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China

Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19

Investor sentiment improved over the past week

Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly

Less than half of directors are independent

Investor sentiment improved over the past week

Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx

Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA